Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Pexelizumab in Patients Undergoing Coronary Artery Bypass Grafting With Cardiopulmonary Bypass (PRIMO-CABG II)

The recruitment status of this study is unknown because the information has not been verified recently.
Verified August 2005 by Alexion Pharmaceuticals.
Recruitment status was  Active, not recruiting
Procter and Gamble
Information provided by:
Alexion Pharmaceuticals Identifier:
First received: July 21, 2004
Last updated: August 28, 2005
Last verified: August 2005
No Study Results Posted on for this Study
  Study Status: This study is ongoing, but not recruiting participants.
  Estimated Study Completion Date: No date given
  Estimated Primary Completion Date: No date given
Publications automatically indexed to this study by Identifier (NCT Number):